FOXE1 and SYNE1 genes hypermethylation panel as promising biomarker in colitis associated colorectal neoplasia

Papadia, Cinzia, Louwagie, Joost, Del Rio, Paolo, Grooteclaes, Madeleine, Coruzzi, Alessandro, Montana, Chiara, Novelli, Marco, Bordi, Cesare, de’ Angelis, Gian Luigi, Bassett, Paul, Bigley, Joseph, Warren, Bryan, Atkin, Wendy and Forbes, Alastair ORCID: https://orcid.org/0000-0001-7416-9843 (2014) FOXE1 and SYNE1 genes hypermethylation panel as promising biomarker in colitis associated colorectal neoplasia. Inflammatory Bowel Diseases, 20 (2). pp. 271-277. ISSN 1078-0998

Full text not available from this repository. (Request a copy)

Abstract

Background: Colitis-associated colorectal cancer affects individuals with inflammatory bowel disease (IBD) more often and earlier than cancer in the general population. Colonoscopy provides the surveillance gold standard. Changes to the surveillance intervals depending on endoscopic activity have been made, given data demonstrating that this is an important predictor of future dysplasia or cancer, but adjuvant, noninvasive clinical tools are still warranted to improve surveillance outcomes and to assist in management and interpretation of dysplasia. Methylation markers may be able to do this. Methods: SYNE1, FOXE1, NDRG4, and PHACTR3 genes were screened using methylation-specific PCR that permit the methylation status of the genes to be determined directly on biopsies. Ninety-three patients with long-standing IBD undergoing a cancer surveillance program, and 30 healthy controls were studied. These included colorectal adenocarcinomas on a background of IBD of various stages (n = 25), IBD-associated dysplastic lesions (n = 29), adenomas arising on a background of ulcerative colitis (n = 8), samples from patients with no evidence of dysplasia or cancer but long-standing IBD (n = 31), and symptomatic patients found to have normal colonoscopy (controls) (n = 30). Results: Gene promotor hypermethylation of SYNE1 and FOXE1 genes varied significantly between the groups and was increasingly likely with increased disease severity. Neither occurred in controls, whereas promotor hypermethylation was detected in biopsies of 60% of patients with colitis-associated colorectal cancer for FOXE1 and 80% for SYNE1. Promotor hypermethylation of either gene was highly significantly different between the groups overall. Conclusions: FOXE1 and SYNE1 hypermethylation markers demonstrated significantly increased expression in neoplastic tissue. Promoter methylation analysis of these genes might be a useful marker of neoplasia in long-standing IBD.

Item Type:	Article
Uncontrolled Keywords:	adenocarcinoma,adult,aged,tumor biomarkers,colitis,colorectal neoplasms,dna methylation,neoplasm dna,disease progression,female,forkhead transcription factors,gene expression regulation, neoplastic,humans,male,middle aged,nerve tissue proteins,nuclear proteins,real-time polymerase chain reaction,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Depositing User:	Pure Connector
Date Deposited:	09 Mar 2015 07:30
Last Modified:	21 Oct 2022 00:37
URI:	https://ueaeprints.uea.ac.uk/id/eprint/52475
DOI:	10.1097/01.MIB.0000435443.07237.ed

Actions (login required)

View Item